Tofacitinib for ulcerative colitis: A promising treatment option

doi:10.3748/wjg.v30.i40.4386

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 40

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (77)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Sum=73

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=1

Oct 28, 2024 (publication date) through Oct 17, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Oct 28, 2024; 30(40): 4386-4392
Published online Oct 28, 2024. doi: 10.3748/wjg.v30.i40.4386

Tofacitinib for ulcerative colitis: A promising treatment option

Zong-Qiang Han, Li-Na Wen

Zong-Qiang Han, Department of Laboratory Medicine, Beijing Xiaotangshan Hospital, Beijing 102211, China

Li-Na Wen, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China

Author contributions: Wen LN designed research; Han ZQ and Wen LN performed research, analyzed data; Han ZQ wrote the letter; Wen LN revised the letter.

Supported by The Scientific Research Cultivation Fund of Capital Medical University, No. PYZ23175.

Conflict-of-interest statement: The two authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Li-Na Wen, Doctor, Research Associate, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Yangfangdian Street, Haidian District, Beijing 100038, China. wenlina3074@bjsjth.cn

Received: July 28, 2024
Revised: September 21, 2024
Accepted: September 26, 2024
Published online: October 28, 2024
Processing time: 79 Days and 23.1 Hours

Core Tip

Core Tip: Tofacitinib can effectively alleviate ulcerative colitis (UC) without being affected by previous tumor necrosis factor antibody therapy. UC may recur after discontinuation of medication, but symptoms will be relieved after resuming tofacitinib administration. While demonstrating effectiveness, tofacitinib has adverse reactions such as herpes zoster and inflammatory reactions. These findings provide doctors with a reference for treating UC in clinical practice. However, more prospective cohort study data are still needed to provide more accurate evidence for the clinical application and safety of tofacitinib.